Axcella, announced that it has activated initial clinical sites and patient screening for its global Phase II clinical trial of AXA1665, the company’s multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy.
[Axcella, Inc.]
7753456
{7753456:nan}
apa
50
1
164091
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
